about
Timing is critical for an effective anti-metastatic immunotherapy: the decisive role of IFNγ/STAT1-mediated activation of autophagyForced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression.Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in miceOptimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patientsComparison of Folate Receptor Targeted Optical Contrast Agents for Intraoperative Molecular Imaging.Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival.Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice.Various ways to improve whole cancer cell vaccines.Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone miceProgrammed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity.Dose-dependent effect of anti-CTLA-4 on survival in sepsis.Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer.
P2860
Q34023964-EB2AA6BF-5040-496E-830E-74D0CE59EA7EQ35013272-BC25DB2D-508F-42F3-9AA3-390AFF3AF7DEQ35157437-7C4F70BE-1E49-417B-842A-1DACF22BEF1DQ35370005-1D0D4CA1-9884-4268-B64D-628AEE5E422FQ35837949-DCBF99EC-D0D8-4730-A1C5-E8657D264CC2Q36057487-C1ADCD48-6199-4214-89DD-6AE931EE8AACQ36146218-867D5430-24E5-4BD0-A57F-2C2E50FD6024Q36185518-A22EE131-9731-41EE-8CE1-06AEE10F2DE2Q36255729-53FFBE90-FD1C-441F-850B-C9A0FDB68B12Q36897208-F4AD3D0D-14C4-4675-AC61-4C8A618A1827Q37729944-0E4595DF-3826-42C7-BEA0-2BA8D404A049Q38206582-25465585-2090-46C8-AFD9-AABA973313D9Q38453610-A6C4DB1B-C4DF-4E95-9524-15675F4A6F3DQ38585990-99811632-1269-4583-963C-CCCDB447D299Q41526077-4B62A114-EA24-4C87-9D45-D53D5FD02E11Q41976084-FD3969A9-B6DF-4F07-9293-A1CE9AE62FB8Q45857246-40A0E049-A355-45DB-99A9-CA48B7384E50
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Targeting inhibitory pathways in cancer immunotherapy.
@ast
Targeting inhibitory pathways in cancer immunotherapy.
@en
type
label
Targeting inhibitory pathways in cancer immunotherapy.
@ast
Targeting inhibitory pathways in cancer immunotherapy.
@en
prefLabel
Targeting inhibitory pathways in cancer immunotherapy.
@ast
Targeting inhibitory pathways in cancer immunotherapy.
@en
P2860
P1476
Targeting inhibitory pathways in cancer immunotherapy.
@en
P2093
Hildegund C J Ertl
Marcio O Lasaro
P2860
P304
P356
10.1016/J.COI.2010.04.005
P577
2010-05-12T00:00:00Z